The statement said the scientific critique details why Merck disagrees with analysis of The Lancet and added that until a study this year, "data from Merck's clinical trials showed no significant difference in cardiovascular risk" of Vioxx.
The British journal strongly criticized the US drug company, which withdrew the drug from the market in September, for failing to stop marketing the drug in 2000 when data showed Vioxx was potentially dangerous.
